DESIGN THERAPEUTICS INC (DSGN) Stock Price, Quote, News and Overview
NASDAQ:DSGN - Nasdaq - US25056L1035 - Common Stock - Currency: USD
DSGN Quote, Performance and Key Statistics
4.36
-0.29 (-6.24%)
The current stock price of DSGN is 4.36 USD. In the past month the price increased by 28.24%. In the past year, price decreased by -4.6%.
DSGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.09 | 346.84B | ||
| AMGN | AMGEN INC | 13.49 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1724.79 | 128.59B | ||
| GILD | GILEAD SCIENCES INC | 13.28 | 128.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.62 | 65.17B | ||
| ARGX | ARGENX SE - ADR | 345.61 | 40.09B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.58B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.40B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.30B | ||
| NTRA | NATERA INC | N/A | 21.40B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.81B | ||
| BIIB | BIOGEN INC | 7.7 | 17.85B |
Related stock screener links
About DSGN
Company Profile
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 54 full-time employees. The company went IPO on 2021-03-26. The company is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Company Info
DESIGN THERAPEUTICS INC
6005 Hidden Valley Road, Suite 110
Carlsbad CALIFORNIA 92011 US
CEO: Joao Siffert
Employees: 54
Phone: 18582934900
DESIGN THERAPEUTICS INC / DSGN FAQ
What is the stock price of DESIGN THERAPEUTICS INC today?
The current stock price of DSGN is 4.36 USD. The price decreased by -6.24% in the last trading session.
What is the ticker symbol for DESIGN THERAPEUTICS INC stock?
The exchange symbol of DESIGN THERAPEUTICS INC is DSGN and it is listed on the Nasdaq exchange.
On which exchange is DSGN stock listed?
DSGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DESIGN THERAPEUTICS INC stock?
9 analysts have analysed DSGN and the average price target is 7.48 USD. This implies a price increase of 71.56% is expected in the next year compared to the current price of 4.36. Check the DESIGN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DESIGN THERAPEUTICS INC worth?
DESIGN THERAPEUTICS INC (DSGN) has a market capitalization of 247.52M USD. This makes DSGN a Micro Cap stock.
How many employees does DESIGN THERAPEUTICS INC have?
DESIGN THERAPEUTICS INC (DSGN) currently has 54 employees.
What are the support and resistance levels for DESIGN THERAPEUTICS INC (DSGN) stock?
DESIGN THERAPEUTICS INC (DSGN) has a support level at 4.35 and a resistance level at 4.66. Check the full technical report for a detailed analysis of DSGN support and resistance levels.
Should I buy DESIGN THERAPEUTICS INC (DSGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DSGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DSGN, evaluating the profitability, health, valuation and growth aspects
- DESIGN THERAPEUTICS INC (DSGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DESIGN THERAPEUTICS INC (DSGN) Sales and EPS estimates to see what analysts future expectations are.
- DESIGN THERAPEUTICS INC (DSGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DESIGN THERAPEUTICS INC (DSGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- DESIGN THERAPEUTICS INC (DSGN) Stock Chart to make your own analysis
- DESIGN THERAPEUTICS INC (DSGN) Latest news and press-releases to stay up to date.
Does DESIGN THERAPEUTICS INC (DSGN) stock pay dividends?
DSGN does not pay a dividend.
When does DESIGN THERAPEUTICS INC (DSGN) report earnings?
DESIGN THERAPEUTICS INC (DSGN) will report earnings on 2025-05-12, after the market close.
What is the Price/Earnings (PE) ratio of DESIGN THERAPEUTICS INC (DSGN)?
DESIGN THERAPEUTICS INC (DSGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).
What is the Short Interest ratio of DESIGN THERAPEUTICS INC (DSGN) stock?
The outstanding short interest for DESIGN THERAPEUTICS INC (DSGN) is 10.15% of its float. Check the ownership tab for more information on the DSGN short interest.
DSGN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to DSGN. When comparing the yearly performance of all stocks, DSGN turns out to be only a medium performer in the overall market: it outperformed 52.06% of all stocks.
DSGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DSGN. While DSGN has a great health rating, there are worries on its profitability.
DSGN Financial Highlights
Over the last trailing twelve months DSGN reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 26.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.67% | ||
| ROE | -20.48% | ||
| Debt/Equity | 0 |
DSGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to DSGN. The Buy consensus is the average rating of analysts ratings from 9 analysts.